- All sections
- A - Human necessities
- A61K - Preparations for medical, dental or toiletry purposes
- A61K 31/513 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
Patent holdings for IPC class A61K 31/513
Total number of patents in this class: 3857
10-year publication summary
|
273
|
303
|
336
|
317
|
293
|
376
|
319
|
342
|
313
|
170
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Abbvie Inc. | 1802 |
86 |
| Merck Sharp & Dohme LLC | 3750 |
58 |
| Taisho Pharmaceutical Co., Ltd. | 869 |
57 |
| Gilead Sciences, Inc. | 2037 |
51 |
| Takeda Pharmaceutical Company Limited | 2714 |
50 |
| Corcept Therapeutics, Inc. | 338 |
49 |
| Immunomedics, Inc. | 267 |
42 |
| Bristol-myers Squibb Company | 4878 |
31 |
| Boehringer Ingelheim International GmbH | 4656 |
30 |
| F. Hoffmann-La Roche AG | 7930 |
29 |
| The Regents of the University of California | 19898 |
29 |
| Genentech, Inc. | 3971 |
27 |
| Novartis AG | 10847 |
25 |
| Pfizer Inc. | 3379 |
22 |
| Cipla Limited | 466 |
22 |
| Isofol Medical AB | 40 |
22 |
| MyoKardia, Inc. | 106 |
22 |
| Merck Sharp & Dohme Corp. | 2197 |
20 |
| Amgen Inc. | 4072 |
20 |
| Celgene Quanticel Research, Inc. | 163 |
20 |
| Other owners | 3145 |